학술논문
Publisher Correction: BIRC2–BIRC3 amplification: a potentially druggable feature of a subset of head and neck cancers in patients with Fanconi anemia.
Document Type
Correction Notice
Author
Source
Subject
*FANCONI'S anemia
*HEAD & neck cancer
*GENE amplification
*CANCER patients
*
*
*
Language
ISSN
2045-2322
Abstract
AZD5582 treatment for 96 h resulted in significant reduction in viability in FA-HNSCC with 11q22.2 amplification compared to 11q22.2 silent tumors or normal cells. The inhibition of BIRC2-3 selectively inhibits growth of FA-HNSCC cell lines with 11q22.2 amplification and no adverse effects on normal cells. Treatment with AZD5582 (500 nM) for 96 h resulted in cell detachment or spheroid disintegration specifically in 11q22.1 amplified FA-HNSCC cells. [Extracted from the article]